Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $118

Benzinga Newsdesk www.benzinga.com Positive 51.1%

Neg 0% Neu 0% Pos 51.1%

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $115 to $118.